CL2016000025A1 - Volasertib en combinación con azacitidina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico. - Google Patents

Volasertib en combinación con azacitidina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.

Info

Publication number: CL2016000025A1
Authority: CL; Chile
Prior art keywords: volasertib; azacitidine; treatment; combination; myeloid leukemia
Prior art date: 2013-07-26

Application number

CL2016000025A

Other languages

English (en)

Inventor

Dorothea Rudolph

Verges Maria Del Roser Calvo

Tillmann Taube

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-26

Filing date

2016-01-07

Publication date

2016-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51228430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-07 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2016-09-30 Publication of CL2016000025A1 publication Critical patent/CL2016000025A1/es

Links

NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title 1
208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
201000003793 Myelodysplastic syndrome Diseases 0.000 title 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
229960002756 azacitidine Drugs 0.000 title 1
SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 title 1
229950003081 volasertib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2016000025A 2013-07-26 2016-01-07 Volasertib en combinación con azacitidina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico. CL2016000025A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361858804P	2013-07-26	2013-07-26

Publications (1)

Publication Number	Publication Date
CL2016000025A1 true CL2016000025A1 (es)	2016-09-30

Family

ID=51228430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2016000025A CL2016000025A1 (es)	2013-07-26	2016-01-07	Volasertib en combinación con azacitidina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.

Country Status (12)

Country	Link
US (3)	US20150031643A1 (es)
EP (1)	EP3024488A1 (es)
JP (1)	JP2016525531A (es)
KR (1)	KR20160035067A (es)
CN (1)	CN105407923A (es)
AU (1)	AU2014295019A1 (es)
CA (1)	CA2919296A1 (es)
CL (1)	CL2016000025A1 (es)
EA (1)	EA201600134A1 (es)
MX (1)	MX2016001087A (es)
PH (1)	PH12016500083A1 (es)
WO (1)	WO2015011235A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2020535112A (ja) *	2017-08-01	2020-12-03	ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓＫｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ	Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
WO2019145410A1 (en) *	2018-01-25	2019-08-01	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US20060063735A1 (en) *	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
US20070117776A1 (en) *	2005-11-04	2007-05-24	John Lyons	Low Dose Therapy Of DNA Methylation Inhibitors
US9358233B2 (en) *	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US8980850B2 (en) *	2011-11-03	2015-03-17	Millennium Pharmaceuticals, Inc.	Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent

2014
- 2014-07-24 CA CA2919296A patent/CA2919296A1/en not_active Abandoned
- 2014-07-24 MX MX2016001087A patent/MX2016001087A/es unknown
- 2014-07-24 AU AU2014295019A patent/AU2014295019A1/en not_active Abandoned
- 2014-07-24 EA EA201600134A patent/EA201600134A1/ru unknown
- 2014-07-24 WO PCT/EP2014/065938 patent/WO2015011235A1/en not_active Ceased
- 2014-07-24 CN CN201480041932.9A patent/CN105407923A/zh active Pending
- 2014-07-24 EP EP14744310.5A patent/EP3024488A1/en not_active Ceased
- 2014-07-24 US US14/340,028 patent/US20150031643A1/en not_active Abandoned
- 2014-07-24 JP JP2016528535A patent/JP2016525531A/ja active Pending
- 2014-07-24 KR KR1020167005131A patent/KR20160035067A/ko not_active Withdrawn
2016
- 2016-01-07 CL CL2016000025A patent/CL2016000025A1/es unknown
- 2016-01-12 PH PH12016500083A patent/PH12016500083A1/en unknown
2017
- 2017-02-24 US US15/441,415 patent/US20170157158A1/en not_active Abandoned
2019
- 2019-04-16 US US16/385,144 patent/US20190240242A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2016525531A (ja)	2016-08-25
US20150031643A1 (en)	2015-01-29
MX2016001087A (es)	2016-04-20
EP3024488A1 (en)	2016-06-01
CA2919296A1 (en)	2015-01-29
US20170157158A1 (en)	2017-06-08
AU2014295019A1 (en)	2015-12-17
PH12016500083A1 (en)	2016-04-18
WO2015011235A1 (en)	2015-01-29
KR20160035067A (ko)	2016-03-30
US20190240242A1 (en)	2019-08-08
EA201600134A1 (ru)	2016-07-29
CN105407923A (zh)	2016-03-16

Publication	Publication Date	Title
EP3484366A4 (en)	2020-10-14	LAPAROSCOPIC EXTENSION OXIMETRY DEVICE
EP3436526A4 (en)	2020-03-25	CELLULOSIC COMPOSITES COMPRISING WOOD PULP
DE112014004591A5 (de)	2016-08-18	Kältegerät
DK2853289T3 (da)	2019-07-15	Anordning, der kan implanteres under huden
EP3583451A4 (en)	2020-12-23	REFLECTIVE ARTICLE INCLUDING A DELAY TIMER
DE112014003539A5 (de)	2016-05-04	Fahrzeug mit riemenscheibe und standklimatisierung
PL2978779T3 (pl)	2020-07-27	Kompozycja tworząca warstwę izolacyjną i jej zastosowanie
IL242163B (en)	2019-08-29	Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
DK2961835T3 (da)	2019-07-22	Ny bakteriophag og antibakteriel sammensætning omfattende samme
EP3466453C0 (en)	2025-09-17	DEODORIZATION MODULE AND STORAGE DEVICE INCLUDING A DEODORIZATION MODULE
PT3493812T (pt)	2023-03-30	Combinações de imetelstat e venetoclax para o tratamento da leucemia mielóide aguda
EP2944674A4 (en)	2015-12-30	POLYAMIDE COMPOSITION AND FORM BODY
EP3913058C0 (en)	2025-01-01	OLIGONUCLEOTIDES COMPRISING MODIFIED NUCLEOSIDES
EP2960327A4 (en)	2016-08-03	IMMUNOSTIMULATION MEDIUM
IL272163A (en)	2020-03-31	Methods of treating myelodysplastic syndrome
EP2973738A4 (en)	2016-11-02	FREE STANDING METALLIC ARTICLE WITH OVER METALLIZATION
DK2792274T3 (da)	2016-05-09	Hyldeknægt med totrinsstøtte.
IL244234B (en)	2019-09-26	Metal pallet with assemblable components
CL2016000024A1 (es)	2016-09-30	Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
ES1094613Y (es)	2014-02-21	Dispositivo aspirador para la eliminación de parásitos presentes en el cabello.
JP2015101303A5 (es)	2015-07-16
EP3493682C0 (en)	2024-03-20	COMPOSITION COMPRISING DUDDINGTONIA FLAGRANS
IL246331B (en)	2020-06-30	A lighting device, and a frame as part of it
JP2015101487A5 (es)	2016-12-08
ES2525735R1 (es)	2015-03-06	Soporte anti-vibratorio con dispositivo para el bloqueo de basamentos